Idiopathic Thrombocytopenic Purpura
📧 Sign up to get email alerts when something new happens for Idiopathic Thrombocytopenic Purpura.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-21EMA Authorised: Eltrombopag Accord (eltrombopag olamine) — Accord Healthcare S.L.U.
EMA authorises Eltrombopag Accord for idiopathic thrombocytopenic purpura (ITP).
-
EMA approval · 2026-02-26EMA Authorised: Revolade (eltrombopag) — Novartis Europharm Limited
The EMA authorized Revolade (eltrombopag). It covers idiopathic thrombocytopenic purpura and aplastic anaemia.
-
EMA approval · 2026-01-08EMA Authorised: Wayrilz (rilzabrutinib) — Sanofi B.V.
The EMA authorised Wayrilz (rilzabrutinib) for idiopathic thrombocytopenic purpura, designated as an orphan medicine in the EU.
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) [Phase 2]
Phase 2 clinical trial evaluating lusutrombopag for immune thrombocytopenia has completed, assessing its potential to raise platelet counts …
-
EMA approval · 2025-10-15EMA Authorised: Nplate (romiplostim) — Amgen Europe B.V.
EMA authorised marketing of Nplate (romiplostim) for idiopathic thrombocytopenic purpura (ITP) in the European Union. The decision confirms …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 [Phase 3]
Completed Phase 3 study of fostamatinib (R788) in chronic idiopathic thrombocytopenic purpura (ITP); results have been posted by sponsor Kis…
-
CLINICAL_TRIALS research · 2025-07-04Clinical Trial Update: An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias [Phase 1, Phase 2]
Open-label Phase 1/2 study evaluating povetacicept in autoimmune cytopenias. The study includes immune thrombocytopenia and idiopathic throm…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients [Phase 2]
Phase 2 safety and efficacy study of PG2 for idiopathic thrombocytopenic purpura has completed.
-
EMA approval · 2025-05-28EMA Authorised: Privigen (human normal immunoglobulin (IVIg)) — CSL Behring GmbH
Privigen (human normal immunoglobulin IVIg) has been authorised by the EMA for multiple indications. The listed therapeutic areas include id…
-
CLINICAL_TRIALS research · 2025-01-03Clinical Trial Update: Special Drug Use-results Survey for Long-term Use (Fostamatinib)
A long-term use results survey for fostamatinib in chronic idiopathic thrombocytopenic purpura is being conducted, with the study currently …
-
CLINICAL_TRIALS trial_result · 2024-07-05Clinical Trial Update: Safety Study of AMG 531 in Japanese Subjects With ITP [Phase 2]
Phase 2 safety study of romiplostim (AMG 531) in Japanese subjects with immune thrombocytopenia has completed. The study evaluated thrombocy…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). [Phase 1]
Phase 1 trial of BI 655064 for chronic primary immune thrombocytopenic purpura (ITP) in adults was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP [Phase 3]
A Phase 3 comparative study comparing GNR-069 with Nplate for efficacy and safety in idiopathic thrombocytopenic purpura has completed.
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura [Phase 2]
Phase 2 trial update evaluating eltrombopag with pulsed dexamethasone for immune thrombocytopenia (idiopathic thrombocytopenic purpura) has …
-
CLINICAL_TRIALS trial_result · 2023-10-19Clinical Trial Update: Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP [Phase 2]
Phase 2 trial comparing eltrombopag plus diacerein versus eltrombopag alone in adult thrombocytopenia (ITP).
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy [Phase 3]
Phase 3 trial evaluating AMG 531 for treatment of thrombocytopenia in idiopathic thrombocytopenic purpura (ITP) patients prior to splenectom…
-
CLINICAL_TRIALS trial_result · 2022-11-07Clinical Trial Update: AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy [Phase 3]
Phase 3 trial update for AMG 531 in thrombocytopenic patients with idiopathic thrombocytopenic purpura (ITP) refractory to splenectomy.
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 clinical trial evaluating baricitinib for steroid-resistant/relapse immune thrombocytopenia (ITP).
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient [Phase 3]
A multicentre Phase III trial evaluated the efficacy and safety of hetrombopag olamine in idiopathic thrombocytopenic purpura (ITP); the stu…
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases [Phase 2]
Phase 2 clinical trial evaluating low-dose IL-2 to induce regulatory T cells in various autoimmune and inflammatory diseases; trial complete…
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Open Label Extension Study of AMG 531 in Japanese Subjects With ITP [Phase 2, Phase 3]
Open-label extension study of AMG 531 in Japanese subjects with immune thrombocytopenic purpura (ITP) completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-01-10Clinical Trial Update: Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) [Phase 2]
Phase 2 trial evaluating romiplostim for immune thrombocytopenic purpura (ITP) has completed with posted results.
-
FDA approval · 2019-10-17FDA Approved: NPLATE — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for NPLATE (romiplostim) from Amgen.
-
CLINICAL_TRIALS trial_result · 2019-09-10Clinical Trial Update: The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) [Phase 3]
Phase 3 trial comparing dexamethasone alone to dexamethasone plus rituximab in newly diagnosed idiopathic thrombocytopenic purpura (ITP) com…
-
CLINICAL_TRIALS trial_result · 2019-03-22Clinical Trial Update: Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
Clinical trial update documenting completion and posted results for a drug use surveillance study related to Takecab as a supplement to Heli…